Amyloidosis, Immunoglobulin-Related: Multimedia

References

1. UAMS researchers ID 17 genes that lead to high-risk myeloma. Updated: April 9, 2007. Fox16.com. Available at http://www.fox16.com/news/local/story/UAMS-researchers-ID-17-genes-that-lead-to-high/km2T2OFQGEKoCaRCIcjv3Q.cspx. Accessed February 11, 2009.

2. Kyle RA, Gertz MA. Primary systemic amyloidosis: clinical and laboratory features in 474 cases. Semin Hematol. Jan 1995;32(1):45-59. [Medline].

3. Leibovitch I, Selva D, Goldberg RA, et al. Periocular and orbital amyloidosis: clinical characteristics, management, and outcome. Ophthalmology. Sep 2006;113(9):1657-64. [Medline].

4. Cross TJ, Wendon JA, Quaglia A, et al. Myeloma associated amyloidosis presenting as subacute liver failure. Postgrad Med J. Jul 2006;82(969):e13. [Medline].

5. Dispenzieri A, Lacy MQ, Katzmann JA, et al. Absolute values of immunoglobulin free light chains are prognostic in patients with primary systemic amyloidosis undergoing peripheral blood stem cell transplantation. Blood. Apr 15 2006;107(8):3378-83. [Medline]. [Full Text].

6. Porrata LF, Gertz MA, Litzow MR, et al. Early lymphocyte recovery predicts superior survival after autologous hematopoietic stem cell transplantation for patients with primary systemic amyloidosis. Clin Cancer Res. Feb 1 2005;11(3):1210-8. [Medline]. [Full Text].

7. Pan WH, Li NP. Clinical pathological feature of early tongue amyloidosis. Chin Med Sci J. Jun 2006;21(2):104-6. [Medline].

8. Kyle RA, Gertz MA, Greipp PR, et al. A trial of three regimens for primary amyloidosis: colchicine alone, melphalan and prednisone, and melphalan, prednisone, and colchicine. N Engl J Med. Apr 24 1997;336(17):1202-7. [Medline]. [Full Text].

9. Skinner M, Anderson J, Simms R, et al. Treatment of 100 patients with primary amyloidosis: a randomized trial of melphalan, prednisone, and colchicine versus colchicine only. Am J Med. Mar 1996;100(3):290-8. [Medline].

10. Gertz MA, Lacy MQ, Lust JA, et al. Prospective randomized trial of melphalan and prednisone versus vincristine, carmustine, melphalan, cyclophosphamide, and prednisone in the treatment of primary systemic amyloidosis. J Clin Oncol. Jan 1999;17(1):262-7. [Medline]. [Full Text].

11. Anderson K, Richardson P, Chanan-Khan A, et al. Single-agent bortezomib in previously untreated multiple myeloma (MM): results of a phase II multicenter study [abstract 7504]. J Clin Oncol. 2006;24:423s.

12. Dispenzieri A, Zhang L, Fonseca R, et al. Single agent bortezomib is associated with a high response rate in patients with high risk myeloma. A phase II study from the Eastern Cooperative Oncology Group (E2A02) [abstract 3527]. Blood. 2006;108(11):1006s. [Full Text].

13. Harousseau JL, Attal M, Leleu X, et al. Bortezomib plus dexamethasone as induction treatment prior to autologous stem cell transplantation in patients with newly diagnosed multiple myeloma: results of an IFM phase II study. Haematologica. Nov 2006;91(11):1498-505. [Medline]. [Full Text].

14. Lee AI, Munshi NC. Integration of novel agents into treatment of myeloma. Clin Lymphoma Myeloma. Aug 2007;7(suppl 5):S215-21. [Medline].

15. Jagannath S, Durie BG, Wolf J, et al. Bortezomib therapy alone and in combination with dexamethasone for previously untreated symptomatic multiple myeloma. Br J Haematol. Jun 2005;129(6):776-83. [Medline].

16. Oakervee HE, Popat R, Curry N, et al. PAD combination therapy (PS-341/bortezomib, doxorubicin and dexamethasone) for previously untreated patients with multiple myeloma. Br J Haematol. Jun 2005;129(6):755-62. [Medline].

17. Popat R, Oakervee HE, Curry N, et al. Reduced dose PAD combination therapy (PS-341/bortezomib, Adriamycin and dexamethasone) for previously untreated patients with multiple myeloma [abstract 2554]. Blood. 2005;106:171a-718a. [Full Text].

18. Jakubowiak AJ, Al-Zoubi A, Kendall T, et al. High rate of complete and near complete responses (CR/nCR) after initial therapy with bortezomib (Velcade®), Doxil®, and dexamethasone (VDD) is further increased after autologous stem cell transplantation (ASCT) [abstract 3093]. Blood. 2006;108:882a. [Full Text].

19. Tran Thang NN, Abdo G, Martin JB, et al. Percutaneous cementoplasty in multiple myeloma: a valuable adjunct for pain control and ambulation maintenance. Support Care Cancer. Aug 2008;16(8):891-6. [Medline].

20. Gianni L, Bellotti V, Gianni AM, Merlini G. New drug therapy of amyloidoses: resorption of AL-type deposits with 4'-iodo-4'-deoxydoxorubicin. Blood. Aug 1 1995;86(3):855-61. [Medline]. [Full Text].

21. Biehn SE, Moore DT, Voorhees PM, et al. Extended follow-up of outcome measures in multiple myeloma patients treated on a phase I study with bortezomib and pegylated liposomal doxorubicin. Ann Hematol. Mar 2007;86(3):211-6. [Medline].

22. Browning MJ, Banks RA, Tribe CR, et al. Ten years' experience of an amyloid clinic--a clinicopathological survey. Q J Med. Mar 1985;54(215):213-27. [Medline].

23. Buxbaum J, Gallo G. Nonamyloidotic monoclonal immunoglobulin deposition disease. Light-chain, heavy-chain, and light- and heavy-chain deposition diseases. Hematol Oncol Clin North Am. Dec 1999;13(6):1235-48. [Medline].

24. Camoriano JK, Greipp PR, Bayer GK, Bowie EJ. Resolution of acquired factor X deficiency and amyloidosis with melphalan and prednisone therapy. N Engl J Med. Apr 30 1987;316(18):1133-5. [Medline].

25. Davern S, Tang LX, Williams TK, et al. Immunodiagnostic capabilities of anti-free immunoglobulin light chain monoclonal antibodies. Am J Clin Pathol. Nov 2008;130(5):702-11. [Medline]. [Full Text].

26. Dispenzieri A, Kyle R, Merlini G, et al. International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders. Leukemia. Nov 20 2008;epub ahead of print. [Medline].

27. Gertz MA, Kyle RA, Greipp PR. Response rates and survival in primary systemic amyloidosis. Blood. Jan 15 1991;77(2):257-62. [Medline]. [Full Text].

28. Harousseau JL. The allogeneic dilemma. Bone Marrow Transplant. Dec 2007;40(12):1123-8. [Medline]. [Full Text].

29. Jagannath S, Durie BGM, Wolf JL, et al. Long-term follow-up of patients treated with bortezomib alone and in combination with dexamethasone as frontline therapy for multiple myeloma [abstract 796]. Blood. Nov 2006;108:238a. [Full Text].

30. Kyle RA. High-dose therapy in multiple myeloma and primary amyloidosis: an overview. Semin Oncol. Feb 1999;26(1):74-83. [Medline].

31. Pelosi F Jr, Capehart J, Roberts WC. Effectiveness of cardiac transplantation for primary (AL) cardiac amyloidosis. Am J Cardiol. Feb 15 1997;79(4):532-5. [Medline].

32. Richardson PG, Barlogie B, Berenson J, et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med. Jun 26 2003;348(26):2609-17. [Medline]. [Full Text].

33. Rubinow A, Skinner M, Cohen AS. Digoxin sensitivity in amyloid cardiomyopathy. Circulation. Jun 1981;63(6):1285-8. [Medline].

34. Simons M, Isner JM. Assessment of relative sensitivities of noninvasive tests for cardiac amyloidosis in documented cardiac amyloidosis. Am J Cardiol. Feb 1 1992;69(4):425-7. [Medline].

35. Solomon A, Weiss DT, Murphy C. Primary amyloidosis associated with a novel heavy-chain fragment (AH amyloidosis). Am J Hematol. Feb 1994;45(2):171-6. [Medline].

36. van Gameren II, Hazenberg BP, Bijzet J, van Rijswijk MH. Diagnostic accuracy of subcutaneous abdominal fat tissue aspiration for detecting systemic amyloidosis and its utility in clinical practice. Arthritis Rheum. Jun 2006;54(6):2015-21. [Medline]. [Full Text].

37. Yood RA, Skinner M, Rubinow A, Talarico L, Cohen AS. Bleeding manifestations in 100 patients with amyloidosis. JAMA. Mar 11 1983;249(10):1322-4. [Medline].

Further Reading

Keywords

immunoglobulin-related amyloidosis, amyloidosis, immunoglobulin, AL, light chain amyloidosis, primary amyloidosis, primary systemic amyloidosis, myeloma-associated amyloidosis, Ig-related amyloidosis, monoclonal plasma cell dyscrasias, monoclonal plasma cell disorder, amyloid deposits, amyloid L chain type, multiple myeloma, monoclonal gammopathy of undetermined significance, MGUS, nonamyloid monoclonal immunoglobulin deposition disease, MIDD, lymphoproliferative disorders

Contributor Information and Disclosures

Author

Slavomir Urbancek, MD, PhD, Head, Department of Dermatology, FD Roosevelt Hospital, Slovakia; Scientific Secretary, Slovak Dermatovenereological Society
Slavomir Urbancek, MD, PhD is a member of the following medical societies: American Academy of Dermatology, European Academy of Dermatology and Venereology, Slovak Dermatovenereological Society, and Slovak Society of Allergology and Clinical Immunology
Disclosure: Nothing to disclose.

Coauthor(s)

Pere Gascon, MD, PhD, Professor and Director, Division of Medical Oncology, Institute of Hematology and Medical Oncology, IDIBAPS, University of Barcelona Faculty of Medicine, Spain
Pere Gascon, MD, PhD is a member of the following medical societies: Alpha Omega Alpha, American College of Physicians, New York Academy of Medicine, New York Academy of Sciences, and Sigma Xi
Disclosure: Nothing to disclose.

Robert A Schwartz, MD, MPH, Professor and Head, Dermatology, Professor of Pathology, Pediatrics, Medicine, and Preventive Medicine and Community Health, UMDNJ-New Jersey Medical School
Robert A Schwartz, MD, MPH is a member of the following medical societies: Alpha Omega Alpha, American Academy of Dermatology, American College of Physicians, and Sigma Xi
Disclosure: Nothing to disclose.

Daniel R Jacobson, MD, Professor of Medicine, Boston University School of Medicine; Chief of Oncology, Veterans Affairs Boston Healthcare System
Disclosure: Nothing to disclose.

Joel Buxbaum, MD, Professor, Department of Molecular and Experimental Medicine, The Scripps Research Institute
Joel Buxbaum, MD is a member of the following medical societies: American Society for Clinical Investigation, American Society of Human Genetics, and Association of American Physicians
Disclosure: Nothing to disclose.

Carol A Bogdan, MD, Consulting Staff, Coastal Cancer Center, Myrtle Beach, SC
Disclosure: Nothing to disclose.

Medical Editor

Robert E Wolf, MD, PhD, Professor Emeritus, Department of Medicine, Louisiana State University Health Sciences Center at Shreveport; Chief, Rheumatology Section, Medical Service, Overton Brooks Veterans Administration Medical Center of Shreveport
Robert E Wolf, MD, PhD is a member of the following medical societies: American College of Rheumatology, Arthritis Foundation, and Society for Leukocyte Biology
Disclosure: Nothing to disclose.

Pharmacy Editor

Francisco Talavera, PharmD, PhD, Senior Pharmacy Editor, eMedicine
Disclosure: Nothing to disclose.

Managing Editor

Lawrence H Brent, MD, Associate Professor of Medicine, Thomas Jefferson University; Chair, Program Director, Department of Medicine, Division of Rheumatology, Albert Einstein Medical Center
Lawrence H Brent, MD is a member of the following medical societies: American Association of Immunologists, American College of Physicians, and American College of Rheumatology
Disclosure: Genentech Honoraria Speaking and teaching; Genentech Grant/research funds Other; Amgen Honoraria Speaking and teaching; Wyeth Honoraria Speaking and teaching; Abbott Immunology Honoraria Speaking and teaching

CME Editor

Rajalaxmi McKenna, MD, FACP, Consulting Staff, Department of Medicine, Southwest Medical Consultants, SC, Good Samaritan Hospital, Advocate Health Systems
Rajalaxmi McKenna, MD, FACP is a member of the following medical societies: American Society of Clinical Oncology, American Society of Hematology, and International Society on Thrombosis and Haemostasis
Disclosure: Nothing to disclose.

Chief Editor

Emmanuel C Besa, MD, Professor, Department of Medicine, Division of Hematologic Malignancies, Kimmel Cancer Center, Thomas Jefferson University
Emmanuel C Besa, MD is a member of the following medical societies: American Association for Cancer Education, American College of Clinical Pharmacology, American Federation for Medical Research, American Society of Hematology, and New York Academy of Sciences
Disclosure: Nothing to disclose.